Opinion|Videos|August 8, 2024
Esketamine Safety Mechanisms and Bioavailability
Geoffrey Grammer, MD closes this series highlighting the administration options of esketamine, its safety profile, and the importance of monitoring patients using this treatment.
Advertisement
Advertisement
Related to this article
As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Advertisement
Advertisement
Trending on HCPLive
1
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
2
Anti-Alpha-Gal Antibodies Block IgE Binding in Alpha-Gal Syndrome
3
Nearly 9 in 10 US Adults With CKD Don't Know They Have It, With Pranav Garimella
4
Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes
5